


Tissue-Source Effect on the Safety and Efficacy of MSCs as Living Biodrugs to Treat Heart Failure:

A Systematic Review And Meta-Analysis of RCTs


Moaz Safwan, Mariam Safwan, Mohamed Aldoush, Khawaja Husnain Haider

Department of Basic Sciences, Sulaiman Al Rajhi University, PO Box-777, AlBakriyyah-51941,
Kingdom of Saudi Arabia.


Supplementary Data





Supplementary Figure 1 Forest Plot of LVEF change from baseline to 6 months of follow-up when both cell types are compared with the unified control.




Supplementary Figure 2 Forest Plot of LVEF change from baseline to 12 follow-up months when both cell types are compared with the unified control.




Supplementary Figure 3 Funnel Plot showing the risk of publication bias in the meta-analysis of LVEF.

(A)**(B)**

Supplementary Figure 4 Forest Plot of 6MWD change from baseline to 6 months of follow-up: (A) BM-MSCs, (B) UC-MSCs, (C) UC-MSCs, and BM-MSCs when compared with the unified control.

(C)



Supplementary Figure 5 Forest Plot of Major Adverse Cardiac Events (A) and rehospitalization rates (B). UC-MSCs and BM-MSCs are compared with the unified control group.

